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Profiles of Serial Changes in Cardiac
Troponin T Concentrations and Outcome in
Ambulatory Patients With Chronic Heart Failure
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Diane E. Grill, MSC,‡ Allan S. Jaffe, MD*†
Rochester, Minnesota
Objectives The purpose of this study was to determine whether different profiles of cardiac troponin T (cTnT) values as-
sessed over time would yield incremental prognostic information on clinically stable outpatients with heart fail-
ure (HF).
Background cTnT levels were used to estimate prognosis in HF; however, most studies evaluated hospitalized patients using
single measurements.
Methods A cohort of 172 New York Heart Association functional class III to IV outpatients was prospectively studied with
serial cTnT measurements collected every 3 months over a 2-year period. The primary end point was death or
cardiac transplantation, and secondary end points included HF hospitalization.
Results Of the 172 patients, 22 (13%) died or underwent transplantation during the first year. Therefore, 150 patients
were included in the second-year analysis of 3 pre-determined groups: 1) no serial cTnT elevations (defined as
0.01 ng/ml); 2) 1 or more, but not all cTnT values elevated 0.01 ng/ml; and 3) all cTnT values elevated dur-
ing the first year. During the second year, 30 events occurred: 53 patients had persistently normal cTnT levels
(0.01 ng/ml) with 6 primary events (11%); 57 patients had 1 or more but not all cTnT levels elevated with 11
events (19%); 40 patients demonstrated persistently elevated cTnT levels with 13 (33%) primary events (odds
ratio: 3.77; 95% confidence interval: 1.28 to 11.07, p  0.02).
Conclusions Elevations in cTnT, even using a low threshold of 0.01 ng/ml, detected during routine clinical follow-up of ambu-
latory patients with HF, are highly associated with an increased risk of events, particularly with frequent or per-
sistent cTnT elevations of 0.01 ng/ml. Therefore, the ability to monitor clinical change through serial cTnT
measurements may add to risk assessment in the ambulatory HF population. (J Am Coll Cardiol 2009;54:
1715–21) © 2009 by the American College of Cardiology Foundation















Hatients with chronic heart failure (HF) manifest progres-
ion of disease over time and an adverse prognosis (1,2) even
n the absence of overt clinical events (3–5). This risk is
ttributable in part to intermittent necrosis that we and
thers have documented based on changes in cardiac tro-
onin T (cTnT) (6–10). Most studies to date have detected
hese changes in cTnT in acutely decompensated hospital-
zed patients. We have reported similar results in stable
mbulatory outpatients with HF (11). The prognosis after
hese events, as with acute presentations with elevations in
TnT, is clearly adverse, suggesting that these small HF
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ccepted July 30, 2009.njuries are analogous to those that lead to acute presenta-
ions but are simply less symptomatic and thus less often
iagnosed. Our results are consonant with those of other
tudies, most of which have been of substantially shorter
uration (6–9). We reported in ambulatory chronic HF
atients that cTnT elevations 0.01 ng/ml (99th percen-
ile of a normal reference population) are associated with
ncreased risks of death/cardiac transplantation and HF-
elated hospitalizations, both at baseline and during
ollow-up (11). It is not clear, however, whether specific
rofiles of cTnT levels over time might provide additional
nformation. Accordingly, we evaluated the profiles of
hange in serial cTnT measurements every 3 months over a
-year period in clinically stable outpatients with New York
eart Association (NYHA) functional classes III and IV
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Serial cTnT Values in Chronic Heart Failure October 27, 2009:1715–21measurements would provide in-
cremental risk stratification infor-
mation in addition to that of single
baseline values in predicting ad-
verse cardiac-related events. If
so, these findings might lead to
an understanding of what types
and timing of intervention might
be effective in the management
of these at-risk patients.
ethods
atients and study design. A cohort of 200 patients with
YHA functional classes III and IV HF was prospectively
nrolled during the period of June 2001 to January 2004 to
ssess the value of serial monitoring of cTnT and natriuretic
eptides in an outpatient HF cohort. These patients were
ecruited from the Mayo Clinic outpatient HF clinic after
nitial evaluation and establishment of routine clinical fol-
ow-up; every effort was made to coordinate clinical and
tudy-related activities. Informed consent was obtained
rom all patients after a primary medical evaluation had
etermined their clinical status. Patients were followed up in
he HF clinic with visits scheduled at 3-month intervals (3
eeks) for a total of 24 months. Patients were excluded if
oronary revascularization was anticipated within 6 months,
f the patient had been listed for cardiac transplantation, or
f they had experienced an episode of acute decompensation
ithin the 30 days before anticipated enrollment. The study
as approved by the Mayo Foundation Institutional Review
oard and included only those patients who provided
ritten informed consent for clinical research analysis as
equired by Minnesota Statute 144.335/CFR 21 (Part 50).
he average duration of HF at study enrollment was 41.9
4.2 months with a median of 31 months.
tudy protocol. Blood for cTnT samples was drawn at
tudy entry (baseline) and at every 3-month follow-up visit
hereafter for 2 years. Samples for cTnT were assayed at the
ime of collection for each patient visit. Clinicians and
nvestigators were blinded to biomarker results. Blood
amples were also obtained for plasma electrolytes, serum
reatinine, and hemoglobin as clinically indicated. Left
entricular ejection fraction was derived from 2-dimensional
chocardiography performed within 3 months of study
nrollment and subsequently during routine clinical
ollow-up as determined by the patient’s HF clinic provider.
n addition to blood samples obtained for the measurement
f biomarkers, an updated patient history was obtained,
nterim clinical status (such as hospitalizations) was deter-
ined, and a physical examination was performed at each
ollow-up visit. Any change in medications was recorded.
hanges in the patients’ medical regimens were undertaken
y the primary HF cardiologist and not by the study
Abbreviations
and Acronyms
BNP  B-type natriuretic
peptide
CI  confidence interval
cTnT  cardiac troponin T
HF  heart failure
NYHA  New York Heart
Association
OR  odds rationvestigator or nurse coordinator. Survival was evaluated suring follow-up for each member of the study cohort. The
ecords from all hospitalizations were reviewed. The deter-
ination of a hospitalization for decompensated HF re-
uired the administration of intravenous diuretics, positive
notropic agents, and/or vasodilators. The mean overall
ollow-up duration was 18.9  7.8 months (range 0.13 to
6.4 months) and 24 months in all survivors.
TnT measurements and estimated renal function. An
levated cTnT was defined as a value 99th percentile of
ormal reference population corresponding to values 0.01
g/ml. Analyses were done using this recommended European
ociety of Cardiology/American College of Cardiology guide-
ine cut point (12,13). Analyses were undertaken based on the
ata during year 1 to assess profiles of cTnT levels, and these
rofiles were then tested during the second year of follow-up.
enal function was determined at study enrollment (baseline)
nd at subsequent visits every 3 months by calculation of the
stimated glomerular filtration rate (ml/min/1.73 m2) using
he Modification of Diet in Renal Disease equation (14) to
llow evaluation of the extent to which cTnT changes were
elated to alterations in renal function.
tatistical analysis. Analyses were done using SAS soft-
are version 9 (SAS Institute Inc., Cary, North Carolina) or
sing S-Plus software version 7.0 (Insightful Corp., Seattle,
ashington). Data for continuous variables are reported as
ean  SD and categorical variables as number and
ercentage of total cohort. The primary end point was the time
ntil death or cardiac transplantation. The cTnT levels at study
nrollment and over the first year of follow-up were grouped
nto profiles of changes in cTnT, and these groups were used
o assess the risk of events occurring during the second year of
he study. Patients were only considered at risk in this analysis
f they were still alive and enrolled after year 1.
Baseline variables were measured at the start of year 1.
ifferences between the cTnT profiles were assessed with
earson’s chi-square test for categorical variables or
-way analysis of variance for continuous variables. Pear-
on’s chi-square test was used to test for differences
etween the patterns and event rates in year 2. Multivar-
ate logistic regression models were fit for death or
ardiac transplantation during year 2 as the dependent
ariable and the cTnT patterns as the independent
ariables. Two models were fit, 1 that had separate
ariables for those with 50% of cTnT normal values
but not all normal) and 1 that had 50% elevated values
but not all elevated). In the second model, these 2 groups
ere combined into 1 variable. Results are presented as
dds ratios (ORs) with corresponding 95% confidence
ntervals (CIs) and p values. Due to the limited number
f events, we ran separate models for each covariate to
ssess its impact on the cTnT results. The Kaplan-Meier
vent curve presented represents the serial measurements
f cTnT and accounts for changes that a patient demon-
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f the 200 patients enrolled, 10 patients had insufficient
ata to be included in the study (no study enrollment
iomarker data) and 18 patients had only baseline entry
easurements without follow-up measurements. Therefore,
72 patients composed the final first-year study cohort. Of
hese 172 patients, 22 (13%) died or underwent transplan-
ation during the first year. Therefore, 150 patients re-
ained to compose the second-year group for analysis.
hree pre-determined patterns of cTnT levels were estab-
ished: 1) no serial cTnT elevations (defined as 0.01
g/ml) in follow-up; 2) 1 or more, but not all, cTnT values
ere elevated (0.01 ng/ml); and 3) all serial cTnT values
ere elevated (0.01 ng/ml) during the first year of follow-
p. The clinical and demographic characteristics of the
urviving patients at the beginning of year 2 of follow-up as
function of the pre-defined cTnT profiles are shown in
able 1. Overall, ischemic and nonischemic etiologies of
F were fairly equally distributed in this patient cohort
80 of 150 [53%] ischemic vs. 70 of 150 [47%] nonisch-
mic).
rimary end point (death or cardiac transplantation)
nalysis of serial cTnT patterns over time. Figure 1
hows the event rates that occurred during year 2 of
ollow-up that were associated with the observed year 1
TnT profiles of change. Overall, 30 events (death or
ransplantation) occurred during the second year of the
tudy. Of the 150 patients, 53 patients had persistently
ormal cTnT levels 0.01 ng/ml (Group 1) with an 11%
vent rate. Of the 57 patients who had 1 or more but not all
TnT levels elevated in year 1 (Group 2), 11 (19%) patients
ad events during year 2. When this group was subdivided
urther (Fig. 1), 21 patients had 50% normal (but not all
ormal) cTnT values (i.e., 0.01 ng/ml) and 36 patients
ad 50% elevated (but not all elevated) cTnT 0.01
g/ml. The latter group had a higher event rate in year 2
10% compared with 25%, p  0.038). Forty patients
emonstrated persistently elevated cTnT levels (Group 3),
nd of these patients, 13 (33%) experienced a primary end
oint event. These results were significant using the chi-
quare test (p  0.04), probably because of the influence of
hose whose cTnT levels were constantly elevated. Those
atients with 50% of serial cTnT elevated values or all
TnT levels persistently elevated experienced a higher event
ate (29%) during the second year. Figure 2 reflects the
aplan-Meier analyses for primary outcomes in year 2 of
ollow-up. Multivariate logistic modeling for death versus
he proportion of elevated cTnT values with adjustment for
ovariates of risk was also done. Due to the small number of
vents, separate models for each of the covariates were run
o assess their impact on the cTnT results. This analysis did
ot affect the overall results (conclusions were unchanged),
nd cTnT remained the strongest independent risk predic-
or (p  0.01) of HF-related events (ischemic and nonisch-
mic etiology [p  0.11], renal function [p  0.22], eypertension [p  0.86], NYHA functional class [p 
.13], atrial fibrillation [p  0.39], and sex [p  0.03]).
Because our previous report (11) had suggested that
atients with cTnT levels 0.03 ng/ml were at even greater
isk of events, we assessed the same cTnT groupings using
his higher cut-point value (0.03 ng/ml). The results are also
hown in Figure 1. Although the same profiles occurred, the
vent rates were higher in each subgroup, increasing to 45%
n those with persistent elevations in cTnT 0.03 ng/ml
p  0.01 relative to Groups 1 and 2).
When comparing the cTnT groups (Table 2), logistic
egression analysis revealed the same gradient of risk,
lthough not all differences were statistically significant.
atients with all serial cTnT values elevated versus none
levated had the highest risk with an OR of 3.77 and a 95%
I of 1.29 to 11.07 (p  0.02). For those with 50% (but
ot all) elevated serial cTnT levels, the OR was 2.61 (95%
I: 0.84 to 8.13) compared with those without any serial
levations. For those patients with 1 or more elevated cTnT
alues (but not all) versus no elevated values in follow-up,
he OR was 1.87 with a wide 95% CI of 0.64 to 5.49 and
as not statistically significant (p  0.25). Patients with
50% (but not all) serial normal values had an OR of 0.83
95% CI: 0.15 to 4.45, p  0.82), which was not different
rom those with persistently normal cTnT levels throughout
he study.
The significance of isolated versus consecutive elevations
n cTnT during the first year was also analyzed. Of those
ith varying levels of cTnT in year 1, 57 patients had 1 or
ore serial cTnT elevations, and of these, 11 (19%) had
vents (p  0.022, compared with not having any eleva-
ions). A single isolated elevation in cTnT was the most
ommon finding (23 of 57 patients, 40%), and after that, the
ost common was 2 consecutive elevations (20 of 57
atients, 35%). The highest number of consecutive eleva-
ions observed was 4, and this occurred in only 2 patients
4%) with neither of these patients experiencing an event.
hus, we were unable to distinguish differences related to
he profile of elevations from the absolute number of
levations.
Hospitalizations for decompensated HF occurred in 60
40%) patients with an overall total of 150 HF-related
ospitalizations during the course of the study. As shown in
able 1, any elevation in cTnT was associated with an
pproximately 50% incidence of hospitalization, whereas in
hose patients without any elevations in cTnT during the
rst year, the occurrence of HF-related hospitalization in
ear 2 was relatively low at 19%.
iscussion
he results of this study provide novel findings regarding
he prognostic significance of serial cTnT measurements
bserved during clinical follow-up of clinically stable, am-
ulatory patients with chronic HF. Importantly, frequent
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Serial cTnT Values in Chronic Heart Failure October 27, 2009:1715–21aseline Patient Demographic and Clinical Characteristics by cTnT Profiles During Year 1 of Clinical Follow-UpTable 1 Baseline Patient Demographic and Clinical Characteristics by cTnT Profiles During Year 1 of Clinical Follow-Up
Variable
No Serial Elevations in cTnT
(<0.01 ng/ml)
(n  53)
1 or More But Not All Serial cTnT Elevated
(>0.01 ng/ml)
(n  57)
All Serial cTnT Elevated
(>0.01 ng/ml)
(n  40) p Value*
Age, yrs 68.4 9.8 73.2 8.2 72.8 10.7 0.018
Sex 0.033
Male 37 (70) 39 (68) 36 (90)
Female 16 (30) 18 (32) 4 (10)
Race 0.55
Caucasian 53 (100) 56 (98) 39 (98)
Native American 0 (0) 1 (2) 1 (3)
NYHA functional class 0.54
III 51 (96) 53 (93) 39 (98)
IV 2 (4) 4 (7) 1 (3)
Diagnosis to enrollment, months 41.2 49.1 46.8 48.4 42.5 41.0 0.81
LVEF, % 28.0 10.8 27.1 12.6 27.9 13.0 0.91
Weight, kg 89.0 23.1 82.1 21.1 92.4 25.5 0.08
Height, cm 172.0 7.0 171.1 9.9 173.3 9.6 0.48
BMI, kg/m2 29.9 6.9 27.9 5.7 30.9 8.4 0.08
Heart rate, beats/min 70.5 14.2 70.4 11.8 70.2 11.5 0.99
Systolic BP, mm Hg 112.3 18.5 117.7 24.0 113.8 18.9 0.39
Diastolic BP, mm Hg 63.7 11.6 64.3 11.8 61.4 8.8 0.43
Hemoglobin, g/dl 13.0 1.6 12.5 1.9 12.3 1.8 0.29
Creatinine, mg/dl 1.4 0.5 1.6 0.5 1.9 0.7 0.001
GFR, ml/min/1.73 m2 53.4 14.9 44.9 14.4 40.9 16.6 0.001
Potassium, mEq/l 4.5 0.5 4.5 1.4 4.4 0.5 0.64
Sodium, mEq/l 139.8 3.4 138.9 4.6 138.5 4.9 0.32
cTnT, ng/ml 0.0 0.0 0.1 0.9 0.1 0.1 0.42
Primary etiology of HF 0.19
Ischemic 28 (53) 34 (60) 18 (45)
Valvular 3 (6) 3 (5) 0 (0)
Idiopathic 19 (36) 15 (26) 13 (33)
Hypertension 0 (0) 2 (4) 2 (5)
Other 3 (6) 3 (5) 7 (18)
Diabetes 13 (25) 15 (26) 17 (43) 0.13
Hypertension 27 (51) 39 (68) 29 (73) 0.06
Hyperlipidemia 34 (64) 35 (61) 26 (65) 0.93
COPD 14 (26) 18 (32) 10 (25) 0.74
CABG 20 (38) 28 (49) 16 (40) 0.45
BiV PPM 2 (4) 4 (7) 2 (5) 0.75
AICD 9 (17) 18 (32) 11 (28) 0.20
Myocardial infarction 22 (42) 30 (53) 18 (45) 0.49
Cerebrovascular disease: stroke 2 (4) 2 (4) 5 (13) 0.13
History of ever smoking 35 (66) 38 (67) 23 (58) 0.61
Atrial fibrillation 15 (28) 32 (56) 21(53) 0.008
Aortic stenosis (moderate to severe) 6 (11) 3 (5) 1 (3) 0.21
Aortic regurgitation 14 (26) 16 (28) 8 (20) 0.65
Mitral regurgitation 37 (70) 42 (74) 26 (65) 0.66
Tricuspid regurgitation (moderate to severe) 10 (19) 16 (28) 7 (18) 0.37
Valve replacement 2 (4) 8 (14) 2 (5) 0.10
ACE inhibitor 39 (74) 44 (77) 33 (83) 0.60
ARB 10 (19) 9 (16) 4 (10) 0.50
Beta-blocker 42 (79) 47 (82) 28 (70) 0.33
Digoxin 27 (51) 37 (65) 24 (60) 0.32
Diuretic agent 43 (81) 53 (93) 38 (95) 0.05
Spironolactone 12 (23) 10 (18) 11 (28) 0.50
Aspirin 32 (60) 33 (58) 22 (55) 0.87
Nitrates 13 (25) 14 (25) 14 (35) 0.45
Antiarrhythmic agents 8 (15) 13 (23) 8 (20) 0.59
Death/cardiac transplant 6 (11) 11 (19) 13 (33) 0.040
Hospitalization for HF 10 (19) 30 (53) 20 (50) 0.001
Death/transplantation or hospitalization for HF 16 (30) 30 (53) 24 (60) 0.009
alues are presented as mean  SD or n (%). *p values obtained using Pearson’s chi-square test for categorical variables and 1-way analysis of variance for continuous variables.
ACE  angiotensin-converting enzyme; AICD  automatic implantable cardioverter-defibrillator; ARB  angiotensin receptor blocker; BiV PPM  biventricular permanent pacemaker; BMI  body massndex; BP  blood pressure; CABG  coronary artery bypass graft; COPD  chronic obstructive pulmonary disease; cTnT  cardiac troponin T; GFR  glomerular filtration rate; HF  heart failure; LVEF 
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rofile, were a potent predictor of increased mortality or the
eed for cardiac transplantation. Only a modest number of
atients had cTnT elevations at all follow-up visits, and the
isk of events was similar to those who manifested 50%
ut 100% elevations in cTnT values (25% vs. 33%,
espectively). Thus, frequent elevations, although intermit-
ent, seem to produce a significant prognostic effect. These
ndings suggest that the progression of HF is likely related
o ongoing necrosis and the magnitude of injury. Such a
oncept is supported by the data showing that higher values
f cTnT elevation (0.03 ng/ml vs. 0.01 ng/ml) were asso-
Figure 1 Cardiac Troponin T Profiles and Outcomes
Association of year 2 events (death/cardiac transplantation) with profiles of cardia
Figure 2 Cardiac Troponin T Profiles and Risk of Events
Kaplan-Meier analysis of the risk of death or cardiac transplantation in
year 2 based on cardiac troponin T patterns from year 1 of clinical follow-up.Ciated with higher event rates. We were unable to discern
ifferences in the timing of these events, which were often
ntermittent, suggesting that they may occur in a stepwise
ashion rather than in a continuous manner. If so, these
pisodes of elevations in cTnT may be analogous to those
hat result in hospital admissions and are often associated
ith an adverse prognosis, but are simply less often de-
ected.
The prognostic value of single-sample baseline elevations
n cTnT has been reported by us (11) and others (9,16–19).
n our cohort, 103 (54%) patients had baseline elevations of
TnT 0.01 ng/ml. Among these, 49 (26%) patients
emonstrated elevations 0.03 ng/ml, which is consistent
ith the frequency seen in other studies (20–23). In
ddition, we have reported the prognostic significance of the
erial measurements of elevations in cTnT occurring at any
isk of Death/Transplantation in Year 2 Basedn cTnT Profiles During Year 1 of Clinical Follow-UpTable 2 Risk of Death/Transplantation in Year 2 Basedon cTnT Profiles During Year 1 of Clinical Follow-Up
cTnT Patterns Odds Ratio (95% CI) p Value
All cTnT levels normal (0.01 ng/ml) vs.
50% normal but not all normal
0.83 (0.15–4.45) 0.82
One or more but not all cTnT levels
elevated vs. all normal levels
1.87 (0.64–5.49) 0.25
50% cTnT levels elevated but not all
elevated vs. all normal levels
2.61 (0.84–8.13) 0.10
All cTnT levels elevated vs. all normal
levels (0.01 ng/ml)
3.77 (1.28–11.07) 0.02















































































































1720 Miller et al. JACC Vol. 54, No. 18, 2009
Serial cTnT Values in Chronic Heart Failure October 27, 2009:1715–21ime during clinical follow-up (11). Even modest elevations
n cTnT were independently associated with an increased
hort-term risk of death or exacerbation of HF generally
ccurring within 3 months of the detected change in cTnT
evel. Changes in cTnT levels occurring during follow-up
lso modulated the risk with new elevations shifting patients
o higher risk and, importantly, reductions in cTnT levels to
0.01 ng/ml reducing risk. This would be consistent with
he findings of this study and suggests that not only are
aseline and follow-up values of cTnT useful but also that
he frequency of cTnT elevations identifies patients at
arious stages of risk. The data from the current analysis
rovide the substrate for clinical trials to investigate whether
onitoring cTnT levels to mitigate risk will improve out-
omes. Treatment trials predicated on biomarker values to
uide therapy are topical, and several have been reported to
how benefit using B-type natriuretic peptide (BNP) and
-terminal proBNP (24–27). In our study cohort, changes
n cTnT levels were shown to be more predictive than BNP
evels, likely because only modest decreases in BNP values
ere observed during treatment (11). We have also reported
hat large changes in natriuretic peptides are necessary to
ffect prognosis (28). Thus, even these initial positive results
ight be improved still further with more aggressive treat-
ent regimens. These results indicate that the differences in
TnT profiles are associated with differences in risk, and,
herefore, serial cTnT measurements may provide another
eans to follow patients and to titrate therapy. These
ndings also suggest that the impact of cTnT elevations is
umulative and that several recurrent elevations are needed
o have a significant impact on prognosis. It is certainly
easonable to hypothesize that mitigating cTnT increases
ight result in better outcomes. This concept is supported
y the fact that those patients with infrequent serial eleva-
ions in cTnT, and particularly normalization of cTnT
evels, seem to temper the ongoing risk of death and
F-related hospitalizations.
Patients with persistent elevations in cTnT values in the
rst year clearly had the highest risk of death or transplantation
n the second year (OR: 3.77, p  0.02). The magnitudes of
he elevations in cTnT were, however, modest compared with
hose reported for hospitalized patients (19,29). Thus, it may
e that larger elevations (0.03 ng/ml) or third and fourth
odest serial elevations result in hospitalization, whereas
rst and second elevations or those that are very modest in
agnitude do not. Such speculation would be consistent
ith our data. Approximately one-half of the elevations that
e observed in cTnT were eventually associated with HF
ospitalizations. We did not include values obtained during
ospitalizations in this analysis because they were sporadic
nd used a variety of assays, and sampling was not done in
consistent manner. In the patients with more frequent
levations of cTnT and those patients with more than 1 (but
ot all) elevated cTnT value, 20 of 40 (50%) and 30 of 57
53%), respectively, were hospitalized during the second
ear of follow-up for decompensated HF. Thus, these tlevations may presage or at least be similar in prognostic
mportance to those associated with more severe events
20–22). If so, even modest elevations in cTnT without
vert clinical decompensation may reflect similar patho-
hysiology, but only detectable by the serial monitoring of
iomarkers such as cTnT. Our findings suggest that both
linically detectable and, importantly, subclinical myocardial
njury may occur. Such events are consistent with myocyte
njury/necrosis and/or apoptosis (6–8,17,19) and the con-
ept of small heart failure myocardial infarctions that
ontribute to progressive deterioration in myocardial func-
ion. These events, however, should be clearly distinguished
rom acute infarctions due to coronary artery abnormalities
ecause we believe that these HF-related events are more
ikely related to subendocardial demand ischemia/necrosis
r apoptosis-induced myocardial stretch and/or toxic cyto-
ines (23,30) than to primary coronary artery events. Ab-
ormal rates of cardiomyocyte apoptosis have been de-
cribed in patients with heart failure (31), and the
ntermittent elevations in cTnT may reflect this accelerated
rocess of cell death. Although we cannot absolutely exclude
he participation of coronary artery disease in patients whose
F was related to underlying ischemic heart disease and/or
ndothelial dysfunction, we did analyze for differences in the
rognostic effects of cTnT profiles over time based on an
schemic versus nonischemic etiology of the HF and found
o differences. An additional important covariate to be
onsidered is renal function, which progressively worsened
ith myocardial injury, as reflected in the association of
ecreasing glomerular filtration rate and more frequent
levations in cTnT levels (Table 1). However, in multivar-
ate analysis, cTnT remained the most potent independent
redictor of HF-related events.
tudy limitations. Eighteen patients elected at various
imes during follow-up not to continue participation in the
tudy (6 had completed at least 1 year of follow-up) and 8
atients died after the initial enrollment visit and before the
rst 3-month follow-up visit; therefore, only baseline data
ere available on these patients. Also, due to the relatively
mall sample size and limited number of events, we did not
t multiple covariates in our statistical models, so we were
nable to control for potential confounding variables simul-
aneously and chose to report p values.
linical implications. It seems that intermittent myocar-
ial injury associated with the progression of HF occurs in
pparently clinically stable and ambulatory outpatients. The
onitoring over time of cTnT, which is a very sensitive and
pecific marker of myocardial injury, provides an available
eans of identifying the subgroup of HF patients at highest
isk. An association between elevated cTnT and ventricular
emodeling injury has been suggested (17,19), and our
ndings support a high risk of death or transplantation in
atients with persistently elevated cTnT levels, even using a
ow threshold of 0.01 ng/ml. Our data suggest a stepwise
rogression of disease, which favors the possibility that
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October 27, 2009:1715–21 Serial cTnT Values in Chronic Heart Failurezation if clinically overt events or whether detected only by
levations in cTnT, might be beneficial.
onclusions
he findings show that more frequent elevations in cTnT
etected during routine clinical follow-up of ambulatory
atients with chronic HF are highly associated with an
ncreased short-term risk of death or cardiac transplanta-
ion, as well as the need for HF-related hospitalization. The
trategy of serially monitoring cTnT levels, therefore, may
ave a role in detecting and managing patients with HF
ho are at higher risk, as advocated by others (32). Even
odest elevations (0.01 ng/ml) are highly prognostic of
oor short-term outcomes. Treatment trials predicated on
hese findings should be considered.
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